



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 04/21/2022 17:56  
**Last Report Issued** 12/12/2017 11:05

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 2800B  
**Patient ID** 2800B  
**Chain** 17002242  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 17002242  
**Received** 12/12/2017

**Lab ID** 17002242-001  
**Matrix** Blood  
**Patient Name** 2800B  
**Patient ID** 2800B  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**2800B Lisdexamfetamine as Metabolite, Blood**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Amphetamine	None Detected	ng/mL	5.0	
Synonym(s): Lisdexamfetamine Metabolite				

In children, the mean plasma Amphetamine concentrations approximately 3.5 hours following 30 mg, 50 mg and 70 mg of Lisdexamfetamine were 53 ng/mL, 93 ng/mL and 134 ng/mL, respectively.

In healthy adults, the mean (+/-SD) steady-state plasma concentrations of Amphetamine following 70 mg of Lisdexamfetamine given once daily ranged from a peak of 90+/-30 ng/mL to a trough of 18+/-14 ng/mL.

The whole blood/plasma concentration ratio for Amphetamine was determined to be 0.6 at a blood level of 500 ng/mL and 1.0 at 5000 ng/mL.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.